Gast ::
| Hauptseite > Publikationsdatenbank > Light-Activated Agonist-Potentiator of GABA A Receptors for Reversible Neuroinhibition in Wildtype Mice > print |
| Hauptseite > Publikationsdatenbank > Light-Activated Agonist-Potentiator of GABA A Receptors for Reversible Neuroinhibition in Wildtype Mice > print |
| 001 | 1031972 | ||
| 005 | 20250203133213.0 | ||
| 024 | 7 | _ | |a 10.1021/jacs.4c08446 |2 doi |
| 024 | 7 | _ | |a 0002-7863 |2 ISSN |
| 024 | 7 | _ | |a 1520-5126 |2 ISSN |
| 024 | 7 | _ | |a 1943-2984 |2 ISSN |
| 024 | 7 | _ | |a 10.34734/FZJ-2024-05896 |2 datacite_doi |
| 024 | 7 | _ | |a 39383450 |2 pmid |
| 024 | 7 | _ | |a WOS:001335501100001 |2 WOS |
| 037 | _ | _ | |a FZJ-2024-05896 |
| 082 | _ | _ | |a 540 |
| 100 | 1 | _ | |a Maleeva, Galyna |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Light-Activated Agonist-Potentiator of GABA A Receptors for Reversible Neuroinhibition in Wildtype Mice |
| 260 | _ | _ | |a Washington, DC |c 2024 |b ACS Publications |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1738060575_6609 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Gamma aminobutyric acid type A receptors (GABAARs) play a key role in the mammalian central nervous system (CNS) as drivers of neuroinhibitory circuits, which are commonly targeted for therapeutic purposes with potentiator drugs. However, due to their widespread expression and strong inhibitory action, systemic pharmaceutical potentiation of GABAARs inevitably causes adverse effects regardless of the drug selectivity. Therefore, therapeutic guidelines must often limit or exclude clinically available GABAAR potentiators, despite their high efficacy, good biodistribution, and favorable molecular properties. One solution to this problem is to use drugs with light-dependent activity (photopharmacology) in combination with on-demand, localized illumination. However, a suitable light-activated potentiator of GABAARs has been elusive so far for use in wildtype mammals. We have met this need by developing azocarnil, a diffusible GABAergic agonist-potentiator based on the anxiolytic drug abecarnil that is inactive in the dark and activated by visible violet light. Azocarnil can be rapidly deactivated with green light and by thermal relaxation in the dark. We demonstrate that it selectively inhibits neuronal currents in hippocampal neurons in vitro and in the dorsal horns of the spinal cord of mice, decreasing the mechanical sensitivity as a function of illumination without displaying systemic adverse effects. Azocarnil expands the in vivo photopharmacological toolkit with a novel chemical scaffold and achieves a milestone toward future phototherapeutic applications to safely treat muscle spasms, pain, anxiety, sleep disorders, and epilepsy. |
| 536 | _ | _ | |a 5241 - Molecular Information Processing in Cellular Systems (POF4-524) |0 G:(DE-HGF)POF4-5241 |c POF4-524 |f POF IV |x 0 |
| 536 | _ | _ | |a 5251 - Multilevel Brain Organization and Variability (POF4-525) |0 G:(DE-HGF)POF4-5251 |c POF4-525 |f POF IV |x 1 |
| 536 | _ | _ | |a 5252 - Brain Dysfunction and Plasticity (POF4-525) |0 G:(DE-HGF)POF4-5252 |c POF4-525 |f POF IV |x 2 |
| 536 | _ | _ | |a DFG project G:(GEPRIS)291198853 - FOR 2518: Funktionale Dynamik von Ionenkanälen und Transportern - DynIon - (291198853) |0 G:(GEPRIS)291198853 |c 291198853 |x 3 |
| 536 | _ | _ | |a DFG project G:(GEPRIS)329460521 - Protonentransfer und Substraterkennung in SLC17-Transportern (329460521) |0 G:(GEPRIS)329460521 |c 329460521 |x 4 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Nin-Hill, Alba |0 0000-0002-8670-9031 |b 1 |
| 700 | 1 | _ | |a Wirth, Ulrike |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Rustler, Karin |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Ranucci, Matteo |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Opar, Ekin |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Rovira, Carme |0 0000-0003-1477-5010 |b 6 |
| 700 | 1 | _ | |a Bregestovski, Piotr |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Zeilhofer, Hanns Ulrich |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a König, Burkhard |0 0000-0002-6131-4850 |b 9 |
| 700 | 1 | _ | |a Alfonso-Prieto, Mercedes |0 P:(DE-Juel1)169976 |b 10 |e Corresponding author |u fzj |
| 700 | 1 | _ | |a Gorostiza, Pau |0 0000-0002-7268-5577 |b 11 |e Corresponding author |
| 773 | _ | _ | |a 10.1021/jacs.4c08446 |g p. jacs.4c08446 |0 PERI:(DE-600)1472210-0 |n 42 |p 28822-28831 |t Journal of the American Chemical Society |v 146 |y 2024 |x 0002-7863 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1031972/files/Invoice_202400144_Julich.pdf |
| 856 | 4 | _ | |y OpenAccess |u https://juser.fz-juelich.de/record/1031972/files/maleeva-et-al-2024-light-activated-agonist-potentiator-of-gabaa-receptors-for-reversible-neuroinhibition-in-wildtype.pdf |
| 909 | C | O | |o oai:juser.fz-juelich.de:1031972 |p openaire |p open_access |p OpenAPC |p driver |p VDB |p openCost |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 10 |6 P:(DE-Juel1)169976 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-524 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Molecular and Cellular Information Processing |9 G:(DE-HGF)POF4-5241 |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5251 |x 1 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5252 |x 2 |
| 914 | 1 | _ | |y 2024 |
| 915 | p | c | |a APC keys set |0 PC:(DE-HGF)0000 |2 APC |
| 915 | p | c | |a Local Funding |0 PC:(DE-HGF)0001 |2 APC |
| 915 | p | c | |a DFG OA Publikationskosten |0 PC:(DE-HGF)0002 |2 APC |
| 915 | p | c | |a Helmholtz: American Chemical Society 01/01/2023 |0 PC:(DE-HGF)0122 |2 APC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-21 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 |0 LIC:(DE-HGF)CCBYNCND4 |2 HGFVOC |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1210 |2 StatID |b Index Chemicus |d 2023-10-21 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1200 |2 StatID |b Chemical Reactions |d 2023-10-21 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-13 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J AM CHEM SOC : 2022 |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-13 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1150 |2 StatID |b Current Contents - Physical, Chemical and Earth Sciences |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-13 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b J AM CHEM SOC : 2022 |d 2024-12-13 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-9-20140121 |k INM-9 |l Computational Biomedicine |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)IAS-5-20120330 |k IAS-5 |l Computational Biomedicine |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-9-20140121 |
| 980 | _ | _ | |a I:(DE-Juel1)IAS-5-20120330 |
| 980 | _ | _ | |a APC |
| 980 | 1 | _ | |a APC |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|